Born in France, Dr. Brice Gaudilliere studied Engineering at Ecole Polytechnique before completing an MD-PhD degree from the Harvard-MIT Health Sciences and Technology program and a postdoctoral fellowship at Stanford University (Dr. Garry Nolan laboratory). Research in the Gaudilliere lab combines high parameter mass cytometry (suspension and imaging mass cytometry) with other proteomics approaches to study how the human immune system responds and adapts to physiological or pathological stressors. Ongoing studies focus on several clinical scenarios including, 1) immune mechanisms of surgical recovery and complications (NIGMSR35), 2) pregnancy and preterm birth (NICHDP01, DDCF, BMGF, ITI, MOD), 3) immune dysfunction and outcomes prediction in patients with COVID19 (Fast Grant, CEND award).
Dr. Gaudilliere is a Board-Certified Anesthesiologist and works clinically in the operating room 25% of his time.
The advent of high dimensional flow cytometry has revolutionized our ability to study and visualize the human immune system. The Gaudilliere group combines high parameter mass cytometry (a.k.a Cytometry by Time of Flight Mass Spectrometry, CyTOF), with advanced bio-computational methods to study how the human immune system responds and adapts to acute physiological perturbations. The laboratory currently focuses on two clinical scenarios: surgical trauma and pregnancy.
Deep immune profiling of patients undergoing and recovering from surgery: Using high dimensional mass cytometry, the lab has recently shown that the signaling behavior of specific innate immune cells measured before surgery in patients blood was strongly associated with surgical recovery. Prospective validation of reported immune correlates of surgical recovery are underway. Ongoing work in humans and animal models focuses on the mechanisms by which pre-operative habilitation interventions may alter a patient’s immune state to improve recovery after surgery.
Deep Immune profiling of normal and preterm pregnancy: The Gaudilliere group is an integral component of a multi-disciplinary effort aiming at understanding the mechanisms of preterm birth, and identifying predictive factors of premature delivery. They have now developed a pipeline and the analytical framework to integrate the single-cell analysis of immune signaling networks by mass cytometry and proteomic profiling of secreted serum factors with the precise phenotyping of pregnancy-related clinical outcomes. In a pilot cross-sectional study of non-pregnant women, they identified candidate immune signatures that differentiated women with a history of preterm or term pregnancies. Longitudinal studies in pregnant patients are ongoing to validate these findings.